GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Net Income From Continuing Operations

VRCDF (Verici Dx) Net Income From Continuing Operations : $-4.81 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Verici Dx's net income from continuing operations for the six months ended in Jun. 2024 was $-1.35 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2024 was $-4.81 Mil.

Verici Dx Net Income From Continuing Operations Historical Data

The historical data trend for Verici Dx's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Net Income From Continuing Operations Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
- -8.33 -11.41 -8.73

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Income From Continuing Operations Get a 7-Day Free Trial -5.47 -5.94 -5.27 -3.46 -1.35

Verici Dx Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-4.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Net Income From Continuing Operations
Comparable Companies
LSE:GENI LSE:LLAI LSE:OBD LSE:GDR LSE:PRM LSE:ABDX TMO DHR XSWX:LONN IDXX A SHSE:603259 IQV MTD NTRA WAT LH DGX XPAR:BIM ILMN
Traded in Other Exchanges
VRCI:UK 63V:Germany
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Website
https://www.vericidx.com
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines